Navigation Links
MCTP bought Genomatix NextGen Sequencing analysis stations
Date:3/26/2009

Ann Arbor, MI and Munich (Germany) March 26, 2009 - Genomatix Software, a leading provider of complete solutions for the analysis of Next Generation Sequencing (NGS) data, announced today that the Michigan Center for Translational Pathology (MCTP) at the University of Michigan installed a Genomatix Mining Station (GMS) and a Genomatix Genome Analyzer (GGA) at its labs in Ann Arbor, MI. GMS and GGA are a combination of purpose built high performance hardware and terabytes of proprietary database and software technology combined to provide a turnkey solution for the analysis of NGS data. Together they represent a complete, integrated analysis solution for NGS data, starting with the raw data generated by the sequencer to a molecular level understanding of the biology being studied.

Peter Grant, Chief Executive Officer at Genomatix, USA commented: "Placing our systems in these highly acclaimed labs at the University of Michigan makes us very proud, and confirms that Genomatix' technology is clearly at the leading edge of this important new genomic technologyright in step with the research that is being done here. We have more than a decade of research and development behind many of the tools implemented in this sweeping array of analysis applications, a fact that places us at the very forefront of the NGS data analysis market. We are prepared today for the data avalanche that will inevitably come from the 'next'-next generation of sequencers."

The MCTP was formed in 2005, under the directorship of Dr. Arul Chinnaiyan, M.D., Ph.D.and Howard Hughes Medical Investigator, as a focused initiative to bring research discoveries from molecular medicine to practical, clinical applications for the identification of biomarkers and therapeutic targets for cancers of the prostate, breast, lung, colon, and skin, as well as other diseases. MCTP utilizes innovative omics approaches, cutting-edge high-throughput genomic screening, along with novel bioinformatics and computational analysis to search the human genomes of patients for abnormalities. They comprehensively examine disease development from the foundations of genetic abnormality up through whole body systems, to gain a more integrated, complete insight into the origins of disease.

The Genomatix Mining Station is the first level analysis solution starting at the raw data from the sequencer, delivering ultra fast mapping, SNP detection, expression profiling and splice analysis. Copy number analysis, small RNA analysis and de-novo assembly are following shortly.Results seamlessly feed into second level analysis with the Genomatix Genome Analyzer which puts them into broad biological context, annotates, integrates and visualizes. Clustering, pattern detection, deep transcription factor analysis, phylogeny, correlation and meta-analysis, pathway and network mining are done by the GGA.


'/>"/>

Contact: Klaus May
may@genomatix.de
49-895-997-660
Genomatix Software GmbH
Source:Eurekalert

Related biology news :

1. NIA uses Genomatix in stem cell research, suggests novel transcription factors for stemness
2. Pfizer inks global license to Genomatix Software and databases
3. Genomatix joins Illumina-Connect program
4. Boehringer Ingelheim uses Genomatix Next Generation Sequencing data analysis systems
5. CRG buys Genomatix Next Generation Sequencing analysis solution
6. Genomatix gets patent for comparative genomics method
7. 454 Sequencing uncovers a genetic basis for different social behaviors in wasp
8. 454 Sequencing: Science paper describes a novel, highly efficient method of sequencing ancient DNA
9. UC Irvine receives $2.18M to explore nano advancements in DNA sequencing
10. Microarray sequence capture speeds large-scale resequencing of targeted genomic regions
11. New technique could dramatically lower costs of DNA sequencing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)... Feb. 14, 2017  Wake Forest Baptist Medical Center ... new chief executive officer (CEO). Freischlag joins the medical ... D. McConnell , M.D., who last year announced that ... Medical Center, after leading it since 2008.   ... of Wake Forest Baptist,s academic health system, which includes ...
(Date:2/13/2017)... WASHINGTON , Feb. 13, 2017 Former ... U.S. Senate Judiciary Committee, Janice Kephart of ... regarding President Donald Trump,s "Executive Order: Protecting ... States" (Jan. 27, 2017):  "As President Trump,s ... 9th Circuit has now essentially banned the travel ban, ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... Germany , March 29, 2017 QIAGEN ... STANDARD: QIA) today announced the U.S. launch of its ipsogen ... cleared by the U.S. Food and Drug Administration as a qualitative in vitro ... extracted from EDTA whole blood.* ... ipsogen JAK2 assay is processed on QIAGEN,s Rotor-Gene ® Q MDx ...
(Date:3/29/2017)... TIKVAH, Israel , March ... (NASDAQ: BCLI), a leading developer of adult ... financial results for the year ended December ... highly successful and pivotal year for Brainstorm, with a ... made on clinical, regulatory and operational fronts," said ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
(Date:3/29/2017)... ... March 29, 2017 , ... Bactana Animal Health, a ... the world’s food supply through enhancement of the gut microbiota, today announced the closing ... Connecticut Innovations , New York-based Sustainable Income Capital Management, LLC and a number of ...
Breaking Biology Technology: